Sciwind Biosciences Announces Publication of Discovery, Preclinical, and Phase 1 Clinical Trial Results of Ecnoglutide (XW003) in Molecular Metabolism

Excerpt from the Press Release:

HANGZHOU, China and SAN FRANCISCO, July 11, 2023 /PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced the publication of discovery, preclinical characterization, and Phase 1 clinical trial results of its GLP-1 analog ecnoglutide (XW003) in Molecular Metabolism.

Ecnoglutide is a novel, fatty acid-conjugated long-acting GLP-1 analog consisting of only natural amino acids, which simplifies the manufacturing process compared to some other GLP-1 analogs. In vitro, ecnoglutide showed potent activity that is biased towards cAMP induction over GLP-1 receptor internalization. In rodent models, ecnoglutide showed significant improvements in glycemic control and body weight reduction compared to semaglutide. In a Phase 1 clinical study, ecnoglutide was found to be generally safe and well tolerated with pharmacokinetic properties supporting once-weekly subcutaneous injections.

Ecnoglutide is currently being evaluated in Phase 3 clinical trials for the treatments of type 2 diabetes and obesity in China.

About ecnoglutide (XW003)

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide is a novel, biased, long-acting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and obesity and is safe and well tolerated in Phase 1 and Phase 2 clinical studies and is currently in multiple Phase 3 trials.

Click the button below to read the entire Press Release:

Continue Reading The Press Release